Rheumatoid arthritis in dermatology

Clinics in Dermatology

Volumn 24, Issue 5, 2006, Pages 430-437

  Hata, Tissa ^a   Kavanaugh, Arthur ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ADRENERGIC RECEPTOR BLOCKING AGENT; AZATHIOPRINE; BECAPLERMIN; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; DAPSONE; ETANERCEPT; GOLD SALT; HYALURONIC ACID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ADULT ONSET STILL DISEASE; ARTICLE; CHILL; CYTOPENIA; DERMATITIS; DYSPNEA; ECCHYMOSIS; ERYTHEMA; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATION; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LUPUS LIKE SYNDROME; NAUSEA; NERVE COMPRESSION; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PYODERMA GANGRENOSUM; RASH; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; RHEUMATOID NEUTROPHILIC DERMATOSIS; RHEUMATOID NODULE; SKIN ATROPHY; SKIN INFECTION; SKIN MANIFESTATION; SKIN TRANSPLANTATION; TACHYCARDIA; THORAX PAIN; TREATMENT PLANNING; URTICARIA; VASCULITIS; WARMING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748463030     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.07.008     Document Type: Article

References (121)

1. Kavanaugh A.F.L.P. Clinical immunology. 2nd ed (2001), Harcourt Publishers, London
2. Turesson C., McClelland R.L., Christianson T.J., and Matteson E.L. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study. Arthritis Rheum 50 (2004) 3729-3731
3. Grassi W., De Angelis R., Lapadula G., Leardini G., and Scarpa R. Clinical diagnosis found in patients with Raynaud's phenomenon: a multicentre study. Rheumatol Int 18 (1998) 17-20
4. Carroll G.J., Withers K., and Bayliss C.E. The prevalence of Raynaud's syndrome in rheumatoid arthritis. Ann Rheum Dis 40 (1981) 567-570
5. Saraux A., Allain J., Guedes C., Baron D., Youinou P., and Le Goff P. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 35 (1996) 752-754
6. Wigley F.M., and Flavahan N.A. Raynaud's phenomenon. Rheum Dis Clin North Am 22 (1996) 765-781
7. Herrick A.L., Illingworth K., Blann A., Hay C.R., Hollis S., and Jayson M.I. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 55 (1996) 122-127
8. Blann A.D., Illingworth K., and Jayson M.I. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 20 (1993) 1325-1330
9. Flavahan N.A., Flavahan S., Liu Q., et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43 (2000) 1886-1890
10. Thompson A.E., and Pope J.E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 44 (2005) 145-150
11. Turesson C., and Jacobsson L.T. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 33 (2004) 65-72
12. Gordon D.A., Stein J.L., and Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med 54 (1973) 445-452
13. Sienknecht C.W., Urowitz M.B., Pruzanski W., and Stein H.B. Felty's syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis 36 (1977) 500-507
14. Schumacher H.R., and Gall E.P. Rheumatoid arthritis: an illustrated guide to pathology, diagnosis, and management (1988), JB Lippincott Co, Philadelphia
15. Kaye B.R., Kaye R.L., and Bobrove A. Rheumatoid nodules. Review of the spectrum of associated conditions and proposal of a new classification, with a report of four seronegative cases. Am J Med 76 (1984) 279-292
16. Ahmed S.S., Arnett F.C., Smith C.A., Ahn C., and Reveille J.D. The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. Medicine (Baltimore) 80 (2001) 271-278
17. Ziff M. The rheumatoid nodule. Arthritis Rheum 33 (1990) 761-767
18. Berhard G. Rheumatoid arthritis: etiology, diagnosis, management (1985), JB Lippincott Co, Philadelphia
19. James W., Berger T., and Elston D. Andrew's diseases of the skin: clinical dermatology. 10th edition (2006), WB Saunders, Philadelphia
20. Hessian P.A., Highton J., Kean A., Sun C.K., and Chin M. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 48 (2003) 334-338
21. Kato H., Yamakawa M., and Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol 27 (2000) 1839-1847
22. Ching D.W., Petrie J.P., Klemp P., and Jones J.G. Injection therapy of superficial rheumatoid nodules. Br J Rheumatol 31 (1992) 775-777
23. Breedveld F.C., Valentijn R.M., Westedt M.L., and Weening J.J. Rapidly progressive glomerulonephritis with glomerular crescent formation in rheumatoid arthritis. Clin Rheumatol 4 (1985) 353-359
24. Segal R., Caspi D., Tishler M., Fishel B., and Yaron M. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 31 (1988) 1182-1185
25. Kaye O., Beckers C.C., Paquet P., Arrese J.E., Pierard G.E., and Malaise M.G. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 23 (1996) 253-257
26. Salvarani C., Macchioni P., Mantovani W., et al. Extraarticular manifestations of rheumatoid arthritis and HLA antigens in northern Italy. J Rheumatol 19 (1992) 242-246
27. Suzuki A., Ohosone Y., Obana M., et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 21 (1994) 33-36
28. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., and Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29 (2002) 62-67
29. Voskuyl A.E., Zwinderman A.H., Westedt M.L., Vandenbroucke J.P., Breedveld F.C., and Hazes J.M. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 55 (1996) 190-192
30. Vollertsen R.S., Conn D.L., Ballard D.J., Ilstrup D.M., Kazmar R.E., and Silverfield J.C. Rheumatoid vasculitis: survival and associated risk factors. Medicine (Baltimore) 65 (1986) 365-375
31. Vollertsen R.S., and Conn D.L. Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am 16 (1990) 445-461
32. Scott D.G., and Bacon P.A. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76 (1984) 377-384
33. Geirsson A.J., Sturfelt G., and Truedsson L. Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis 46 (1987) 727-733
34. Sayah A., and English III J.C. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 53 (2005) 191-209 [quiz 210-2]
35. Golding J.R., Hamilton M.G., and Gill R.S. Arteritis of rheumatoid arthritis. Br J Dermatol 77 (1965) 207-210
36. Bywaters E.G., and Scott J.T. The natural history of vascular lesions in rheumatoid arthritis. J Chronic Dis 16 (1963) 905-914
37. Watts R.A., Carruthers D.M., and Scott D.G. Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis 54 (1995) 927-929
38. Voskuyl A.E., Hazes J.M., Zwinderman A.H., et al. Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 62 (2003) 407-413
39. Sigal L.H. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore) 66 (1987) 157-180
40. Matsuo T., Koyama T., Morimoto N., Umezu H., and Matsuo N. Retinal vasculitis as a complication of rheumatoid arthritis. Ophthalmologica 201 (1990) 196-200
41. Scott D.G., Bacon P.A., and Tribe C.R. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 60 (1981) 288-297
42. Babian M., Nasef S., and Soloway G. Gastrointestinal infarction as a manifestation of rheumatoid vasculitis. Am J Gastroenterol 93 (1998) 119-120
43. Mizuno K., Ikeda K., Saida Y., Takenaka R., Shibata M., and Takeuchi T. Hepatic hemorrhage in malignant rheumatoid arthritis. Am J Gastroenterol 91 (1996) 2624-2625
44. Heurkens A.H., Westedt M.L., and Breedveld F.C. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 151 (1991) 2249-2254
45. Upchurch K.S., Heller K., and Bress N.M. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 17 2 Pt 2 (1987) 355-359
46. Unger L., Kayser M., and Nusslein H.G. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 62 (2003) 587-588
47. Hirche D., Rubbert A., Lunau L., Krieg T., and Eming S.A. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab. Br J Dermatol 152 (2005) 1062-1064
48. Knab J., Goos M., and Dissemond J. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. J Eur Acad Dermatol Venereol 19 (2005) 243-246
49. Still G. On a form of chronic joint disease in children. Med Chir Trans 80 (1897) 47
50. Elkon K.B., Hughes G.R., Bywaters E.G., et al. Adult-onset Still's disease. Twenty-year follow-up and further studies of patients with active disease. Arthritis Rheum 25 (1982) 647-654
51. Magadur-Joly G., Billaud E., Barrier J.H., et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54 (1995) 587-590
52. Kadar J., and Petrovicz E. Adult-onset Still's disease. Best Pract Res Clin Rheumatol 18 (2004) 663-676
53. Larson E.B. Adult Still's disease. Evolution of a clinical syndrome and diagnosis, treatment, and follow-up of 17 patients. Medicine (Baltimore) 63 (1984) 82-91
54. Mahmud T., and Hughes G.R. Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol 26 (1999) 2067-2068
55. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., and Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52 (2005) 1794-1803
56. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 137 (1997) 1000-1005
57. Lyon C.C., Smith A.J., Beck M.H., Wong G.A., and Griffiths C.E. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 42 (2000) 992-1002
58. McCalmont C.S., Leshin B., White W.L., Greiss Jr. F.C., and Jorizzo J.L. Vulvar pyoderma gangrenosum. Int J Gynaecol Obstet 35 (1991) 175-178
59. Powell F.C., Su W.P., and Perry H.O. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 34 (1996) 395-409 [quiz 410-2]
60. Callen J.P. Neutrophilic dermatoses. Dermatol Clin 20 (2002) 409-419
61. Adachi Y., Kindzelskii A.L., Cookingham G., et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 111 (1998) 259-268
62. Ko C.B., Walton S., and Wyatt E.H. Pyoderma gangrenosum: associations revisited. Int J Dermatol 31 (1992) 574-577
63. Gardner L.W., and Acker D.W. Triamcinolone and pyoderma gangrenosum. Arch Dermatol 106 (1972) 599-600
64. Braun-Falco M., Stock K., Ring J., and Hein R. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome-associated pyoderma gangrenosum. Br J Dermatol 147 (2002) 829-831
65. de Cock K.M., and Thorne M.G. The treatment of pyoderma gangrenosum with sodium cromoglycate. Br J Dermatol 102 (1980) 231-233
66. Tsele E., Yu R.C., and Chu A.C. Pyoderma gangrenosum-response to topical nitrogen mustard. Clin Exp Dermatol 17 (1992) 437-440
67. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 3 (2002) 149-158
68. Wollina U., and Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol 14 (2000) 187-190
69. Slevin M., Kumar S., and Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 277 (2002) 41046-41059
70. Farris D.R., Schutzer P.J., Don P.C., Silverberg N.B., and Weinberg J.M. Resolution of pyoderma gangrenosum after therapy with lyophilized bovine collagen matrix. Dermatology 206 (2003) 284-285
71. Jolles S., Niclasse S., and Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 140 (1999) 564-565
72. Patrone P., Bragadin G., De Francesco V., Frattasio A., and Stinco G. Pyoderma gangrenosum of the scalp treated with cyclosporine A. Int J Dermatol 41 (2002) 916-918
73. Coors E.A., and von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol 143 (2000) 154-156
74. Kaminska R., Ikaheimo R., and Hollmen A. Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Clin Exp Dermatol 24 (1999) 81-85
75. Burruss J.B., Farmer E.R., and Callen J.P. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 35 5 Pt 1 (1996) 720-724
76. Fukuhara K., Urano Y., Kimura S., Hori K., and Arase S. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 139 (1998) 556-558
77. Kark E.C., Davis B.R., and Pomeranz J.R. Pyoderma gangrenosum treated with clofazimine. Report of three cases. J Am Acad Dermatol 4 (1981) 152-159
78. Hecker M.S., and Lebwohl M.G. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 38 (1998) 490-491
79. Reynolds N.J., and Peachey R.D. Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Derm Venereol 70 (1990) 538-539
80. Lyon C.C., Kirby B., and Griffiths C.E. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br J Dermatol 140 (1999) 562-564
81. Nousari H.C., Lynch W., Anhalt G.J., and Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 134 (1998) 1509-1511
82. Kaur M.R., and Lewis H.M. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol 153 (2005) 689-691
83. Ackerman A. Histopathologic diagnosis of inflammatory skin diseases: a method by pattern analysis (1978), Lea and Febiger, Philadelphia
84. MacAya A., Servitje O., Jucgla A., and Peyri J. Rheumatoid neutrophilic dermatitis associated with pyoderma gangrenosum. Br J Dermatol 142 (2000) 1246-1248
85. Lowe L., Kornfeld B., Clayman J., and Golitz L.E. Rheumatoid neutrophilic dermatitis. J Cutan Pathol 19 (1992) 48-53
86. Mashek H.A., Pham C.T., Helm T.N., and Klaus M. Rheumatoid neutrophilic dermatitis. Arch Dermatol 133 (1997) 757-760
87. Scherbenske J.M., Benson P.M., Lupton G.P., and Samlaska C.P. Rheumatoid neutrophilic dermatitis. Arch Dermatol 125 (1989) 1105-1108
88. Yamamoto T., Ohkubo H., and Nishioka K. Rheumatoid neutrophilic dermatitis. Int J Dermatol 33 (1994) 798-800
89. Hirota T.K., Keough G.C., David-Bajar K., and McCollough M.L. Rheumatoid neutrophilic dermatitis. Cutis 60 (1997) 203-205
90. Harkaway K, Elenitas R, Margolis DJ. Erythematous papules in a patient with rheumatoid arthritis. Rheumatoid neutrophilic dermatitis (RND). Arch Dermatol 1995;131:1196, 1199-200.
91. Sanchez J.L., and Cruz A. Rheumatoid neutrophilic dermatitis. J Am Acad Dermatol 22 5 Pt 2 (1990) 922-925
92. Kavanaugh A., Cohen S., and Cush J.J. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol 31 (2004) 1881-1884
93. Lee S.J., and Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol 116 (2005) 900-905
94. Cush J.J. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 30 (2004) 237-255
95. Zeltser R., Valle L., Tanck C., Holyst M.M., Ritchlin C., and Gaspari A.A. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 137 (2001) 893-899
96. Kugathasan S., Levy M.B., Saeian K., et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97 (2002) 1408-1414
97. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
98. Wasserman M.J., Weber D.A., Guthrie J.A., Bykerk V.P., Lee P., and Keystone E.C. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 31 (2004) 1912-1917
99. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
100. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
101. Mohan N., Edwards E.T., Cupps T.R., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31 (2004) 1955-1958
102. Galaria N.A., Werth V.P., and Schumacher H.R. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 27 (2000) 2041-2044
103. Jarrett S.J., Cunnane G., Conaghan P.G., et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30 (2003) 2287-2291
104. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
105. Guillevin L., and Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 31 (2004) 1885-1887
106. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
107. Bresnihan B., and Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 29 (2003) 185-202
108. Fratazzi C., Arbeit R.D., Carini C., and Remold H.G. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol 158 (1997) 4320-4327
109. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
110. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63 (2004) 1538-1543
111. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48 (2003) 3013-3022
112. Netea M.G., Radstake T., Joosten L.A., van der Meer J.W., Barrera P., and Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 48 (2003) 1853-1857
113. Chan A.T., Cleeve V., and Daymond T.J. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78 (2002) 47-48
114. Baghai M., Osmon D.R., Wolk D.M., Wold L.E., Haidukewych G.J., and Matteson E.L. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 76 (2001) 653-656
115. Flendrie M., Vissers W.H., Creemers M.C., de Jong E.M., van de Kerkhof P.C., and van Riel P.L. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7 (2005) R666-R676
116. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., and Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52 (2005) 2513-2518
117. Verea M.M., Del Pozo J., Yebra-Pimentel M.T., Porta A., and Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 38 (2004) 54-57
118. Thurber M., Feasel A., Stroehlein J., and Hymes S.R. Pustular psoriasis induced by infliximab. J Drugs Dermatol 3 (2004) 439-440
119. Beuthien W., Mellinghoff H.U., and von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 50 (2004) 1690-1692
120. Winterfield L.S., Menter A., Gordon K., and Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 64 Suppl 2 (2005) ii87-ii90 [discussion ii91-2]
121. Sfikakis P.P., and Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 15 (2003) 380-386